Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
BackgroundThe diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a predic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.992929/full |
| _version_ | 1798019880312635392 |
|---|---|
| author | Juan Zhao Madi Guo Yushuai Song Shan Liu Ran Liao Yu Zhang Yumin Zhang Qi Yang Yuanlong Gu Xiaoyi Huang Xiaoyi Huang |
| author_facet | Juan Zhao Madi Guo Yushuai Song Shan Liu Ran Liao Yu Zhang Yumin Zhang Qi Yang Yuanlong Gu Xiaoyi Huang Xiaoyi Huang |
| author_sort | Juan Zhao |
| collection | DOAJ |
| description | BackgroundThe diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a predictor of diagnosis and recurrence for early-stage PDAC.MethodsSerum samples were obtained from patients with 50 PDAC, 6 benign pancreatic tumor (BPT), or 9 chronic pancreatitis (CP) and 50 healthy controls (HCs). Serum exosomes were isolated using an exosome isolation kit. Exosomal and serum GPC-1 levels were measured using ELISA. The freeze–thaw process was carried out to analyze the stability of GPC-1. Receiver operating characteristic (ROC) analysis was employed to assess the diagnostic value of GPC-1. Kaplan–Meier and multivariate Cox analyses were used to evaluate the prognostic value of GPC-1.ResultsThe average concentrations of serum exosomal and serum GPC-1 were 1.5 and 0.8 ng/ml, respectively. GPC-1 expression levels were stable under repeated freezing and thawing (d1-5 freeze–thaw cycles vs. d0 P > 0.05). Serum exosomal and serum GPC-1 were significantly elevated in patients with PDAC compared with HCs (P < 0.0001) but were slightly higher compared with that in patients with CP and BPT (P > 0.05). The expression levels of exosomal and serum GPC-1 were elevated 5 days after surgery in patients with PDAC, CP, and BPT (P < 0.05). Patients with high levels of exosomal and serum GPC-1 had a shorter relapse-free survival (RFS) (P = 0.006, and P = 0.010). Multivariate analyses showed that serum exosomal and serum GPC-1 were independent prognostic indicators for early RFS (P = 0.008, and P = 0.041).ConclusionELISA is an effective and sensitive method to detect exosomal and serum GPC-1. The detection of GPC-1 was stable under repeated freezing and thawing cycles and could distinguish early-stage PDAC from HCs but not CP and BPT. Exosomal and serum GPC-1 may be good independent predictors of early recurrence in early-stage PDAC. |
| first_indexed | 2024-04-11T16:48:04Z |
| format | Article |
| id | doaj.art-2818b4f654b745b5a849d0b7692c98bf |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T16:48:04Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2818b4f654b745b5a849d0b7692c98bf2022-12-22T04:13:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.992929992929Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinomaJuan Zhao0Madi Guo1Yushuai Song2Shan Liu3Ran Liao4Yu Zhang5Yumin Zhang6Qi Yang7Yuanlong Gu8Xiaoyi Huang9Xiaoyi Huang10Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaDepartment of interventional oncology, Taizhou Municipal Hospital, Taizhou, Zhejiang, ChinaBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, ChinaNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, Heilongjiang, ChinaBackgroundThe diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a predictor of diagnosis and recurrence for early-stage PDAC.MethodsSerum samples were obtained from patients with 50 PDAC, 6 benign pancreatic tumor (BPT), or 9 chronic pancreatitis (CP) and 50 healthy controls (HCs). Serum exosomes were isolated using an exosome isolation kit. Exosomal and serum GPC-1 levels were measured using ELISA. The freeze–thaw process was carried out to analyze the stability of GPC-1. Receiver operating characteristic (ROC) analysis was employed to assess the diagnostic value of GPC-1. Kaplan–Meier and multivariate Cox analyses were used to evaluate the prognostic value of GPC-1.ResultsThe average concentrations of serum exosomal and serum GPC-1 were 1.5 and 0.8 ng/ml, respectively. GPC-1 expression levels were stable under repeated freezing and thawing (d1-5 freeze–thaw cycles vs. d0 P > 0.05). Serum exosomal and serum GPC-1 were significantly elevated in patients with PDAC compared with HCs (P < 0.0001) but were slightly higher compared with that in patients with CP and BPT (P > 0.05). The expression levels of exosomal and serum GPC-1 were elevated 5 days after surgery in patients with PDAC, CP, and BPT (P < 0.05). Patients with high levels of exosomal and serum GPC-1 had a shorter relapse-free survival (RFS) (P = 0.006, and P = 0.010). Multivariate analyses showed that serum exosomal and serum GPC-1 were independent prognostic indicators for early RFS (P = 0.008, and P = 0.041).ConclusionELISA is an effective and sensitive method to detect exosomal and serum GPC-1. The detection of GPC-1 was stable under repeated freezing and thawing cycles and could distinguish early-stage PDAC from HCs but not CP and BPT. Exosomal and serum GPC-1 may be good independent predictors of early recurrence in early-stage PDAC.https://www.frontiersin.org/articles/10.3389/fonc.2022.992929/fullpancreatic ductal adenocarcinomaexosomeglypican 1diagnosisearly recurrence |
| spellingShingle | Juan Zhao Madi Guo Yushuai Song Shan Liu Ran Liao Yu Zhang Yumin Zhang Qi Yang Yuanlong Gu Xiaoyi Huang Xiaoyi Huang Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma Frontiers in Oncology pancreatic ductal adenocarcinoma exosome glypican 1 diagnosis early recurrence |
| title | Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| title_full | Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| title_fullStr | Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| title_short | Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| title_sort | serum exosomal and serum glypican 1 are associated with early recurrence of pancreatic ductal adenocarcinoma |
| topic | pancreatic ductal adenocarcinoma exosome glypican 1 diagnosis early recurrence |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.992929/full |
| work_keys_str_mv | AT juanzhao serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT madiguo serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT yushuaisong serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT shanliu serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT ranliao serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT yuzhang serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT yuminzhang serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT qiyang serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT yuanlonggu serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT xiaoyihuang serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma AT xiaoyihuang serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma |